In plain English
Kisspeptin is the hormone at the very top of your reproductive system. It tells the brain to release GnRH, which then signals the testes or ovaries to make testosterone, estrogen and sperm or eggs. Kisspeptin-10 is the short, active end of the molecule and is used to support natural hormone production and libido.
What it's used for
- Supporting natural testosterone production in men
- Fertility support, including during or after testosterone therapy
- Libido and sexual arousal
- Being studied for egg maturation in IVF
Benefits
In human studies, kisspeptin has been shown to:
- Raise LH and testosterone in healthy men within an hour
- Increase activity in brain areas linked to sexual and romantic response
- Trigger safe egg maturation in IVF studies (using kisspeptin-54)
Users report improved libido and support for natural testosterone, especially when coming off testosterone therapy.
How it works
In simple terms: kisspeptin flips the top switch of the reproductive hormone chain.
It binds the KISS1 receptor on GnRH neurons in the hypothalamus, causing them to release GnRH. GnRH tells the pituitary to release LH and FSH, which drive testosterone and sperm production in men and estrogen and egg development in women. Short pulses work best; constant exposure can switch the system off.
Development history
- 1996: The KISS1 gene is discovered in Hershey, Pennsylvania, and named after the town’s chocolate Kisses.
- 2003: Found to be essential for puberty and fertility.
- 2010s: Imperial College London studies kisspeptin in men, women and IVF.
Typical protocols
These ranges are what users commonly report.
| Use | Dose | Frequency | Notes |
|---|---|---|---|
| Testosterone and fertility support | About 100 mcg (roughly 1–2 mcg per kg) | Once daily or a few times a week | Pulsed, not continuous |
| Libido | 100–200 mcg | A few hours before activity | As needed |
Daily, high-dose use can blunt the response over time, so users favour intermittent dosing.
Cycling
Used intermittently or in courses of a few weeks; continuous high-dose use can reduce its effect.
Administration options
Subcutaneous injection.
Reconstitution and dosing calculator
Kisspeptin-10 usually comes in 5 mg or 10 mg vials and is commonly mixed with 2 mL of bacteriostatic water.
Draw your syringe to
– units
- Volume to draw
- –
- Concentration
- –
- Each unit holds
- –
- Doses per vial
- –
Show the math
This tool does arithmetic only. It does not choose a dose or confirm that any substance is right for you. Double-check every result against your syringe and your clinician’s instructions.
Side effects and safety
- Users report that kisspeptin is generally well tolerated. Occasional effects include flushing, headache and injection-site redness.
- Continuous or very frequent dosing can suppress the hormone system it is meant to support.
- Avoid during pregnancy and breastfeeding.
Common stacks
- Gonadorelin or HCG: combined by men protecting fertility during or after testosterone therapy.
- PT-141: combined by some users for libido.
Storage
Powder: refrigerate, dry and away from light.
After mixing: refrigerate at 2–8 °C and use within about 3–4 weeks.
Compare with
- Gonadorelin: works one step lower, as GnRH itself.
- HCG: acts directly on the testes like LH.
- PT-141: boosts desire through melanocortin receptors rather than hormones.
Frequently asked questions
Will kisspeptin raise my testosterone?
In studies it raised LH and testosterone in healthy men. The effect depends on a working pituitary and testes.
Why not use it every day at a high dose?
Constant exposure can switch the system off, so users keep doses moderate and intermittent.
Kisspeptin-10 or kisspeptin-54?
Kisspeptin-10 is the short, fast-acting fragment; kisspeptin-54 is the longer natural form used in most IVF studies.
References
- Dhillo WS, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609-6615.
- Jayasena CN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-3677.